

Applicant herein states that the content of the Sequence Listing information recorded in computer readable form is identical to the paper copy of the Sequence Listing, and includes no new matter.

Please substitute the following amended paragraphs for the identified paragraphs of the pending specification:

The paragraph at page 3, lines 9-12:

A2

A second aspect of the invention provides methods for diagnosis of Alzheimer's disease that comprise detecting in a sample of CSF the presence or level of at least one Alzheimer's Disease-Associated Protein Isoform (API), e.g., one or more of the APIs disclosed herein or any combination thereof (SEQ ID NOs:1-458).

A3

The paragraph from page 24, line 27 to page 25, line 2:

The first group comprises of APIs that are decreased in the CSF of subjects having Alzheimer's disease as compared with the CSF of subjects free from Alzheimer's disease. The amino acid sequences of peptides produced from these APIs by proteolysis using trypsin and identified by tandem mass spectrometry and database searching using the SEQUEST program are listed in Table IV (SEQ ID NOs:1-269), in addition to their corresponding pIs and MWs. For one API, the partial sequence information derived from tandem mass spectrometry was not found to be described in any known public database. This API is listed as 'NOVEL' in Table IV, and the partial amino acid sequence information derived from manually interpreting the MS/MS spectrum of tryptic peptides of this API as described in the Example infra, is given in Table IX (SEQ ID NOs:463, 466, 469, 472, 475, 478, 481, 484, 487).

Please substitute Table IV at page 25, line 3 to page 31, line 2, with the amended Table IV submitted in the attached pages entitled "Table IV". Table IV is amended to include sequence identifiers.

The paragraph at page 31, lines 3-8: